Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On April 9, 2017, Larry Dillaha, M.D., was named the permanent President and Chief Executive Officer of Repros Therapeutics Inc. (the “Company”), and was also appointed to the Company’s Board of Directors (the “Board”). Dr. Dillaha had served as the Company’s President and Chief Executive Officer on an interim basis since February 1, 2017. Dr. Dillaha’s compensation in his role as permanent President and Chief Executive Officer is expected to be determined shortly and will be disclosed at that time.
About Repros Therapeutics Inc. (NASDAQ:RPRX)
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids. Repros Therapeutics Inc. (NASDAQ:RPRX) Recent Trading Information
Repros Therapeutics Inc. (NASDAQ:RPRX) closed its last trading session up +0.06 at 1.09 with 176,723 shares trading hands.
